Clinical Trials Directory

Trials / Completed

CompletedNCT05004168

Sun Protection Factor (SPF) / UVA Protection Factor Study

The Efficacy of Sun Protection Factor (SPF) Against UV-B and UV-A of Cosmetic Products

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Indonesia University · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Evaluation of the effectiveness of sunscreen products by determining its Sun Protection Factor (SPF) against UV-B and UV-A

Detailed description

Sunscreen is intended to protect the skin from sun burn but since the amount of protection needed varies among individuals, sunscreen manufactures offer consumers difference levels of protection. These different levels of protection are expressed as a numerical value called the sun protection factor or SPF. The SPF is the ratio between the minimal erythema dose (MED) of sunscreen product of the protected skin and the MED of the unprotected skin. The minimal erythema dose in human skin is defined as the lowest ultraviolet B (UV-B) dose produces the first perceptible unambigous erythema with defined border appearing over most of the field of UVB exposure 16 - 24 hours after UVB exposure. The UVA protection factor is the ratio between the Minimal Persistent Pigmentation Darkening Dose (MPPDD) of sunscreen product of the protected skin and the MPPDD of the unprotected skin. The threshold response will be taken as an unequivocal pigment darkening with distinct border which persisted for at least 2 hours. The test products are Day Gel-0120-C and Day Gel-0120-D with active ingredients ethylhexyl methoxycinnamate, Diethylamino hydroxybenzoyl hexyl benzoate

Conditions

Interventions

TypeNameDescription
OTHERDay Gel-0120Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
OTHERP5 Reference Standard (SPF 35 reference)The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.

Timeline

Start date
2020-09-02
Primary completion
2020-09-24
Completion
2020-09-24
First posted
2021-08-13
Last updated
2021-08-13

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT05004168. Inclusion in this directory is not an endorsement.